2,905 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Procyon Advisors LLC

Procyon Advisors LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, Holdings Channel.com reports. The firm bought 2,905 shares of the company’s stock, valued at approximately $1,966,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IDXX. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $26,000. WealthCollab LLC bought a new position in IDEXX Laboratories in the 2nd quarter worth $30,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the 3rd quarter worth $31,000. Armstrong Advisory Group Inc. lifted its position in IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new stake in IDEXX Laboratories during the third quarter valued at about $35,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the subject of a number of analyst reports. BTIG Research reduced their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. UBS Group reduced their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Piper Sandler decreased their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

Insiders Place Their Bets

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the transaction, the director owned 648 shares of the company’s stock, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 over the last ninety days. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $577.26 on Monday. The stock’s 50-day simple moving average is $645.73 and its 200-day simple moving average is $664.71. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a market capitalization of $45.90 billion, a price-to-earnings ratio of 44.17, a PEG ratio of 3.50 and a beta of 1.66. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.